AGLE Aeglea BioTherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AGLE

Price (delayed)

$0.128

Market cap

$8.37M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.84

Enterprise value

-$23.75M

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea's lead product ...

Highlights
AGLE's EPS is up by 23% YoY and by 15% QoQ
Aeglea BioTherapeutics's debt has decreased by 10% YoY and by 4.3% QoQ
The net income has declined by 8% year-on-year but it has increased by 7% since the previous quarter
The gross profit has dropped by 94% year-on-year and by 50% since the previous quarter
AGLE's revenue has shrunk by 94% YoY and by 50% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://aegleabio.com
Peers: OVID

Key stats

What are the main financial stats of AGLE
Market
Shares outstanding
65.4M
Market cap
$8.37M
Enterprise value
-$23.75M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.25
Price to sales (P/S)
10.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-20.39
Earnings
Revenue
$1.17M
EBIT
-$78M
EBITDA
-$75.98M
Free cash flow
-$71.52M
Per share
EPS
-$0.84
Free cash flow per share
-$0.76
Book value per share
$0.51
Revenue per share
$0.01
TBVPS
$0.56
Balance sheet
Total assets
$52.45M
Total liabilities
$18.8M
Debt
$4.43M
Equity
$33.65M
Working capital
$31.74M
Liquidity
Debt to equity
0.13
Current ratio
3.51
Quick ratio
3.17
Net debt/EBITDA
0.42
Margins
EBITDA margin
-6,522.2%
Gross margin
100%
Net margin
-6,678.2%
Operating margin
-6,793.6%
Efficiency
Return on assets
-96.7%
Return on equity
-132.1%
Return on invested capital
-245.9%
Return on capital employed
-195.9%
Return on sales
-6,695.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AGLE stock price

How has the Aeglea BioTherapeutics stock price performed over time
Intraday
-1.84%
1 week
-5.33%
1 month
-23.63%
1 year
-82.47%
YTD
-71.55%
QTD
-55.86%

Financial performance

How have Aeglea BioTherapeutics's revenue and profit performed over time
Revenue
$1.17M
Gross profit
$1.17M
Operating income
-$79.15M
Net income
-$77.8M
Gross margin
100%
Net margin
-6,678.2%
The gross profit has dropped by 94% year-on-year and by 50% since the previous quarter
AGLE's revenue has shrunk by 94% YoY and by 50% QoQ
The company's operating margin has shrunk by 87% QoQ
Aeglea BioTherapeutics's net margin has shrunk by 86% QoQ

Growth

What is Aeglea BioTherapeutics's growth rate over time

Valuation

What is Aeglea BioTherapeutics stock price valuation
P/E
N/A
P/B
0.25
P/S
10.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-20.39
AGLE's EPS is up by 23% YoY and by 15% QoQ
AGLE's P/B is 89% below its 5-year quarterly average of 2.3 and 50% below its last 4 quarters average of 0.5
The company's equity fell by 45% YoY and by 33% QoQ
AGLE's revenue has shrunk by 94% YoY and by 50% QoQ
AGLE's price to sales (P/S) is 23% lower than its last 4 quarters average of 13.5

Efficiency

How efficient is Aeglea BioTherapeutics business performance
AGLE's return on invested capital has dropped by 170% year-on-year and by 28% since the previous quarter
AGLE's ROS has shrunk by 86% QoQ
The company's return on equity has shrunk by 68% YoY and by 3.9% QoQ
Aeglea BioTherapeutics's ROA has plunged by 57% YoY

Dividends

What is AGLE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AGLE.

Financial health

How did Aeglea BioTherapeutics financials performed over time
Aeglea BioTherapeutics's total assets is 179% higher than its total liabilities
Aeglea BioTherapeutics's total assets has decreased by 37% YoY and by 26% QoQ
Aeglea BioTherapeutics's quick ratio has decreased by 26% YoY and by 19% QoQ
Aeglea BioTherapeutics's debt is 87% lower than its equity
AGLE's debt to equity has surged by 63% year-on-year and by 44% since the previous quarter
The company's equity fell by 45% YoY and by 33% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.